Using TPS ≥ 1% as the cutoff, our cohort had a PD-L1-positive rate of 56.1%, which is consistent with previous reports on Asian populations.[16] Currently, pembrolizumab is the first-line treatment for metastatic NSCLC patients with PD-L1 TPS ≥ 50% in some countries, including China. Here, CD274 is linked to non-small cell lung carcinoma.